Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.
Antonio Ocejo, MD
Advertisement
Articles by Antonio Ocejo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Accelerated Approval to Zongertinib in HER2+ NSCLC
2
Enzalutamide/Radium-223 Extends Survival in mCRPC
3
Olaparib Combo Improves PFS/OS in BRCA+ or ATM+ Metastatic CRPC
4
Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial
5